knowledge -WSS

knowledge

author：fashion 2025-10-02 11:08:11 - browse：6594

Gavel and Stethoscope due process — District courts will make the first round of decisions soon on challenges to Medicare's drug price negotiation program. APStock

WASHINGTON — Pharmaceutical companies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare to negotiate prescription drug prices, will soon face their first big tests.

District court judges could soon weigh in on the litany of court cases that major companies filed against the government — shedding light on whether drugmakers have any hope of postponing the first parts of the negotiation process, scrapping it entirely, or sending the issue up to the Supreme Court.

It’s a major moment for the Biden administration, too, as the White House ramps up its efforts to take credit for the new changes in the 2024 election. The first round of legal decisions will play out in the thick of campaign season, attorneys told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Venture capitalist Bob Kocher on the state of digital health

leisure time

WSS

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Why a market frenzy over new weight loss drugs defies logic

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Merck, Daiichi strike cancer drug pact worth up to $22 billion

hotspot

knowledge

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Trump demands the U.S. pay no more for drugs than other countries … again

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Continuity nursing helped my family in our darkest PICU moments

With measles on the rise, a personal story of a devastating disease

23andMe had bad news about my health. I wish a person had delivered it

STAT Readout Newsletter: Biotech news today

Wikipedia

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Glen Campbell's doctor discusses his public struggle with Alzheimer's

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Data integrity in scientific journals requires "effort" by publishers, institutions

Why a market frenzy over new weight loss drugs defies logic

leisure time

Wikipedia

entertainment

explore